NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it has partnered with Bristol-Myers Squibb to develop a companion diagnostic for a number of cancer immunotherapies, with an initial focus on colorectal cancer (CRC).